Amedisys (AMED) Reports In-Line Q4 EPS

Amedisys (NASDAQ: AMED) reported Q4 EPS of $1.18, in-line with the analyst estimate of $1.18. Revenue for the quarter came in at $559.3 million versus the consensus estimate of $555.2 million.

GUIDANCE:

Amedisys sees FY2022 EPS of $5.23-$5.45, versus the consensus of $5.84. Amedisys sees FY2022 revenue of $2.33-2.365 billion, versus the consensus of $2.37 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS cuts KOSPI target by nearly 10% to reflect higher rates
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2